INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D – MK-3475-06D

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: MK-2870 (experimental drug) or MK-1022 (experimental drug)

Pathologies: Esophageal tumors

ClinicalTrials.gov: Read the details about clinical trials

The study enrolls patients with advanced/metastatic gastroesophageal adenocarcinoma, in second-line with the possibility, based on a 1:1:1 randomization, of three different treatments:

- Arm 1: Ramucirumab + Paclitaxel

- Arm 2: MK 2870 + Paclitaxel

- Arm 3: MK1022 + Ramucirumab

The primary objective is to evaluate the ORR (objective response), that is the number of subjects whose tumor responds (shrinks or disappears) with the treatment.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe